AbbVie Inc. Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax, Portion Attributable to Parent
AbbVie Inc. (ABBV) reported Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax, Portion Attributable to Parent of $1.00 million for the 3-month period ending 2016-09-30, per its 10-Q filed 2016-11-07.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeDerivativesQualifyingAsHedgesTaxPortionAttributableToParent · last filed 2016-11-07
- AbbVie Inc. other comprehensive income (loss), derivatives qualifying as hedges, tax, portion attributable to parent for the quarter ending 2016-09-30 was $1.00M.
- AbbVie Inc. other comprehensive income (loss), derivatives qualifying as hedges, tax, portion attributable to parent for the quarter ending 2016-06-30 was $3.00M.
- AbbVie Inc. other comprehensive income (loss), derivatives qualifying as hedges, tax, portion attributable to parent for the quarter ending 2016-03-31 was -$7.00M, a 450.00% decline year-over-year.
- AbbVie Inc. other comprehensive income (loss), derivatives qualifying as hedges, tax, portion attributable to parent for the quarter ending 2015-12-31 was $1.00M, a 75.00% decline year-over-year.
- AbbVie Inc. other comprehensive income (loss), derivatives qualifying as hedges, tax, portion attributable to parent for fiscal 2015 was -$6.00M, a 175.00% decline from fiscal 2014.
- AbbVie Inc. other comprehensive income (loss), derivatives qualifying as hedges, tax, portion attributable to parent for fiscal 2014 was $8.00M.
- AbbVie Inc. other comprehensive income (loss), derivatives qualifying as hedges, tax, portion attributable to parent for fiscal 2013 was $0.00.
- AbbVie Inc. other comprehensive income (loss), derivatives qualifying as hedges, tax, portion attributable to parent for fiscal 2012 was -$8.00M.
| Period end | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2016-09-30 | $1.00M 10-Q · filed 2016-11-07 | $4.00M derived: sum of 2 quarters · filed 2016-11-07 | -$3.00M 10-Q · filed 2016-11-07 | -$2.00M derived: sum of 4 quarters · filed 2016-11-07 |
| 2016-06-30 | $3.00M 10-Q · filed 2016-08-05 | -$4.00M 10-Q · filed 2016-08-05 | -$3.00M derived: sum of 3 quarters · filed 2016-08-05 | -$8.00M derived: sum of 4 quarters · filed 2016-11-07 |
| 2016-03-31 | -$7.00M 10-Q · filed 2016-05-06 | -$6.00M derived: sum of 2 quarters · filed 2016-05-06 | -$11.00M derived: sum of 3 quarters · filed 2016-11-07 | -$12.00M derived: sum of 4 quarters · filed 2016-11-07 |
| 2015-12-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-19 | -$4.00M derived: sum of 2 quarters · filed 2016-11-07 | -$5.00M derived: sum of 3 quarters · filed 2016-11-07 | -$6.00M 10-K · filed 2016-02-19 |
| 2015-09-30 | -$5.00M 10-Q · filed 2016-11-07 | -$6.00M derived: sum of 2 quarters · filed 2016-11-07 | -$7.00M 10-Q · filed 2016-11-07 | $0.00 derived: sum of 4 quarters · filed 2016-11-07 |
| 2015-06-30 | -$1.00M 10-Q · filed 2016-08-05 | -$2.00M 10-Q · filed 2016-08-05 | $5.00M derived: sum of 3 quarters · filed 2016-08-05 | $11.00M derived: sum of 4 quarters · filed 2016-08-05 |
| 2015-03-31 | $2.00M 10-Q · filed 2016-05-06 | $6.00M derived: sum of 2 quarters · filed 2016-05-06 | $12.00M derived: sum of 3 quarters · filed 2016-05-06 | $12.00M derived: sum of 4 quarters · filed 2016-05-06 |
| 2014-12-31 | $4.00M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-19 | $10.00M derived: sum of 2 quarters · filed 2016-02-19 | $10.00M derived: sum of 3 quarters · filed 2016-02-19 | $8.00M 10-K · filed 2016-02-19 |
| 2014-09-30 | $6.00M 10-Q · filed 2015-11-06 | $6.00M derived: sum of 2 quarters · filed 2015-11-06 | $4.00M 10-Q · filed 2015-11-06 | $8.00M derived: sum of 4 quarters · filed 2015-11-06 |
| 2014-06-30 | $0.00 10-Q · filed 2015-08-07 | $2.00M 10-Q · filed 2015-08-07 | $2.00M derived: sum of 3 quarters · filed 2015-08-07 | $0.00 derived: sum of 4 quarters · filed 2015-08-07 |
| 2014-03-31 | $2.00M 10-Q · filed 2015-05-08 | $2.00M derived: sum of 2 quarters · filed 2015-05-08 | $0.00 derived: sum of 3 quarters · filed 2015-05-08 | $0.00 derived: sum of 4 quarters · filed 2015-05-08 |
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-21 | -$2.00M derived: sum of 2 quarters · filed 2014-11-07 | -$2.00M derived: sum of 3 quarters · filed 2014-11-07 | $0.00 10-K · filed 2014-02-21 |
| 2013-09-30 | -$2.00M 10-Q · filed 2014-11-07 | -$2.00M derived: sum of 2 quarters · filed 2014-11-07 | $0.00 10-Q · filed 2014-11-07 | -$6.00M derived: sum of 4 quarters · filed 2015-02-20 |
| 2013-06-30 | $0.00 10-Q · filed 2014-08-07 | $2.00M 10-Q · filed 2014-08-07 | -$4.00M derived: sum of 3 quarters · filed 2015-02-20 | -$7.00M derived: sum of 4 quarters · filed 2015-02-20 |
| 2013-03-31 | $2.00M 10-Q · filed 2014-05-09 | -$4.00M derived: sum of 2 quarters · filed 2015-02-20 | -$7.00M derived: sum of 3 quarters · filed 2015-02-20 | -$8.00M derived: sum of 4 quarters · filed 2015-02-20 |
| 2012-12-31 | -$6.00M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-20 | -$9.00M derived: sum of 2 quarters · filed 2015-02-20 | -$10.00M derived: sum of 3 quarters · filed 2015-02-20 | -$8.00M 10-K · filed 2015-02-20 |
| 2012-09-30 | -$3.00M 10-Q · filed 2013-11-12 | -$4.00M derived: sum of 2 quarters · filed 2013-11-12 | -$2.00M 10-Q · filed 2013-11-12 | |
| 2012-06-30 | -$1.00M 10-Q · filed 2013-08-09 | $1.00M 10-Q · filed 2013-08-09 | ||
| 2012-03-31 | $2.00M 10-Q · filed 2013-05-08 | |||
| 2011-12-31 | -$8.00M 10-K · filed 2014-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |